Table 1.
Baseline Patient and Disease Characteristics in 205 Subjects
| Characteristic | Value |
|---|---|
| Number of Deaths | 170 (83%) |
| Age at Metastases (years) | 74 (67, 81) |
| Year of Metastases | 2007 (2005, 2010) |
| Race | |
| Non-black | 136 (66%) |
| Black | 69 (34%) |
| Treatment Center | |
| Center 1 | 97 (47%) |
| Center 2 | 108 (53%) |
| Biopsy Gleason score | |
| 2–6 | 31 (15%) |
| 3+4 | 37 (18%) |
| 4+3, 8–10 | 65 (32%) |
| Unknown/No Biopsy | 72 (35%) |
| Local Treatment | |
| None (Watchful Waiting/ADT) | 85 (41%) |
| Radical Prostatectomy ± Radiation | 49 (24%) |
| Radiation Alone | 71 (35%) |
| Number of Bone Metastases | |
| Bone Metastases | 181 (88%) |
| 1 | 36 (18%) |
| 2 | 23 (11%) |
| 3–9 | 69 (34%) |
| ≥10 | 53 (26%) |
| Visceral/Lymph Node Only | 24 (12%) |
| Metastases in Lymph Nodes | 40 (20%) |
| Metastases in Visceral Tissue | 15 (7%) |
| Metastases in Liver | 7 (3%) |
| Metastases in Lung | 1 (<1%) |
| Metastases in Other Soft Tissue | 8 (4%) |
| PSA at Metastases (ng/mL) | 52.4 (19.6, 145.4) |
| PSADT at Metastases (months) | 5.4 (3.4, 10.1) |
| PSAV at Metastases (ng/mL/year) | 33.6 (10.0, 92.7) |
| Total Follow-up (months)* | 40.7 (23.7, 79.9) |
Data are presented as n(%) or median (interquartile range).
Abbreviations: ADT = androgen deprivation therapy; CI = confidence interval; CRPC = castration-resistant prostate cancer; PSA = prostate specific antigen; PSADT = PSA doubling time; PSAV = PSA velocity.
*
Follow-up reported among those alive at last follow-up.